Tatva Chintan Pharma Chem Valuation Multiples

Tatva Chintan Pharma Chem is valued at $465M as of October 2026, a 7.6x revenue multiple. In the last 12 months, Tatva Chintan Pharma Chem revenue was $63M and Tatva Chintan Pharma Chem EBITDA was $13M.

Tatva Chintan Pharma Chem Overview

About Tatva Chintan Pharma Chem

Tatva Chintan makes specialty chemicals such as structure directing agents, phase transfer catalysts and electrolyte salts for pharma, agro and battery customers. It is based in Vadodara.


Founded

1996

HQ

India

Employees

1.1K

Sectors

Financials (LTM)

Revenue: $63M
EBITDA: $13M

EV

$481M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Tatva Chintan Pharma Chem Financials

Tatva Chintan Pharma Chem reported last 12-month revenue of $63M and EBITDA of $13M.

In the same LTM period, Tatva Chintan Pharma Chem generated $35M in gross profit, $13M in EBITDA, and $6M in net income.


Tatva Chintan Pharma Chem P&L

In the most recent fiscal year, Tatva Chintan Pharma Chem reported revenue of $53M and EBITDA of $10M.

Tatva Chintan Pharma Chem is profitable as of last fiscal year, with gross margin of 53%, EBITDA margin of 19%, and net margin of 8%.

See analyst estimates for Tatva Chintan Pharma Chem
LTMLast FY202320242025202620272028
Revenue$63M$53M$42M$40M$50M
Gross Profit$35M$28M$21M$19M$25M
Gross Margin55%53%51%47%51%
EBITDA$13M$10M$7M$5M$9M
EBITDA Margin20%19%17%12%17%
EBIT Margin14%12%12%4%10%
Net Profit$6M$4M$4M$1M$3M
Net Margin10%8%9%3%7%
Net Debt-$12M---

Financial data powered by Morningstar, Inc.

Tatva Chintan Pharma Chem Stock Performance

Tatva Chintan Pharma Chem has current market cap of $465M, and enterprise value of $481M.


Tatva Chintan Pharma Chem's stock price is $19.88.

Tatva Chintan Pharma Chem share price increased by 7.0% in the last 30 days, and by 24.7% in the last year.

Tatva Chintan Pharma Chem has an EPS (earnings per share) of $0.19.

See more trading valuation data for Tatva Chintan Pharma Chem
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$481M$465M-0.7%7.0%6.7%24.7%$0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Tatva Chintan Pharma Chem Valuation Multiples

Tatva Chintan Pharma Chem trades at 7.6x EV/Revenue multiple, and 37.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Financial Valuation Multiples

As of October 22, 2026, Tatva Chintan Pharma Chem has market cap of $465M and EV of $481M.

Tatva Chintan Pharma Chem has a P/E ratio of 74.3x.

LTMLast FY202320242025202620272028
EV/Revenue7.6x9.1x11.4x11.9x9.7x
EV/EBITDA37.6x47.6x66.7x101.8x56.4x
EV/EBIT55.3x76.7x95.4xn/m98.5x
EV/Gross Profit13.8x17.3x22.5x25.2x18.9x
P/E74.3x104.7x129.0xn/m133.5x
EV/FCF(74.1x)(53.6x)(61.8x)(93.3x)(59.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Tatva Chintan Pharma Chem Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Tatva Chintan Pharma Chem Margins & Growth Rates

Tatva Chintan Pharma Chem grew revenue by 35% and EBITDA by 51% in the last fiscal year.

In the most recent fiscal year, Tatva Chintan Pharma Chem reported gross margin of 53%, EBITDA margin of 19%, and net margin of 8%.

See estimated margins and future growth rates for Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Margins

Last FY202420252026202720282029
Gross Margin53%47%51%54%
EBITDA Margin19%12%17%21%
EBIT Margin12%4%10%15%
Net Margin8%3%7%10%
FCF Margin(17%)(13%)(16%)(9%)

Tatva Chintan Pharma Chem Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth35%(4%)23%35%
Gross Profit Growth41%(11%)33%43%
EBITDA Growth51%(34%)80%64%
EBIT Growth75%(66%)185%100%
Net Profit Growth74%(65%)178%99%
FCF Growth(45%)(34%)58%(27%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Tatva Chintan Pharma Chem Operational KPIs

Tatva Chintan Pharma Chem's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

Tatva Chintan Pharma Chem's Rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tatva Chintan Pharma Chem's Rule of X is 108% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Tatva Chintan Pharma Chem
LTMLast FY202320242025202620272028
Rule of 4047%56%---
Bessemer Rule of X88%108%---
Revenue per Employee-$0.0M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue-6%6%7%6%
Opex to Revenue-41%39%43%41%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Tatva Chintan Pharma Chem Competitors

Tatva Chintan Pharma Chem competitors include Filatex India, Grupa Azoty, Creta Plastics, Laxmi Organic Indus, Alujain, Foseco India, Ellenbarrie Industrial, Uflex, Gujarat Themis Biosyn and Prasol Chemicals.

Most Tatva Chintan Pharma Chem public comparables operate across Chemicals.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Filatex India$439M$34M1.0x-13.5x-
Grupa Azoty$3.4B($841M)0.9x0.9x(3.7x)12.4x
Creta Plastics$441M$70M0.8x-4.9x-
Laxmi Organic Indus$293M$20M1.8x1.1x26.5x11.9x
Alujain$347M($296M)2.1x1.6x(2.5x)7.4x
Foseco India$68M$11M6.5x-40.5x-
Ellenbarrie Industrial$34M$11M14.3x10.6x43.3x30.8x
Uflex$1.6B$193M0.9x-7.4x-

This data is available for Pro users. Sign up to see all Tatva Chintan Pharma Chem competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Tatva Chintan Pharma Chem

When was Tatva Chintan Pharma Chem founded?Tatva Chintan Pharma Chem was founded in 1996.
Where is Tatva Chintan Pharma Chem headquartered?Tatva Chintan Pharma Chem is headquartered in India.
How many employees does Tatva Chintan Pharma Chem have?As of today, Tatva Chintan Pharma Chem has over 1K employees.
Is Tatva Chintan Pharma Chem publicly listed?Yes, Tatva Chintan Pharma Chem is a public company listed on Bombay Stock Exchange.
What is the stock symbol of Tatva Chintan Pharma Chem?Tatva Chintan Pharma Chem trades under 543321 ticker.
When did Tatva Chintan Pharma Chem go public?Tatva Chintan Pharma Chem went public in 2021.
Who are competitors of Tatva Chintan Pharma Chem?Tatva Chintan Pharma Chem main competitors include Filatex India, Grupa Azoty, Creta Plastics, Laxmi Organic Indus, Alujain, Foseco India, Ellenbarrie Industrial, Uflex, Gujarat Themis Biosyn, Prasol Chemicals.
What is the current market cap of Tatva Chintan Pharma Chem?Tatva Chintan Pharma Chem's current market cap is $465M.
What is the current revenue of Tatva Chintan Pharma Chem?Tatva Chintan Pharma Chem's last 12 months revenue is $63M.
What is the current revenue growth of Tatva Chintan Pharma Chem?Tatva Chintan Pharma Chem revenue growth (NTM/LTM) is 27%.
What is the current EV/Revenue multiple of Tatva Chintan Pharma Chem?Current revenue multiple of Tatva Chintan Pharma Chem is 7.6x.
What is the current EBITDA of Tatva Chintan Pharma Chem?Tatva Chintan Pharma Chem's last 12 months EBITDA is $13M.
What is Tatva Chintan Pharma Chem's EBITDA margin?Tatva Chintan Pharma Chem's last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Tatva Chintan Pharma Chem?Current EBITDA multiple of Tatva Chintan Pharma Chem is 37.6x.
What is the current FCF of Tatva Chintan Pharma Chem?Tatva Chintan Pharma Chem's last 12 months FCF is ($6M).
What is Tatva Chintan Pharma Chem's FCF margin?Tatva Chintan Pharma Chem's last 12 months FCF margin is (10%).
What is the current EV/FCF multiple of Tatva Chintan Pharma Chem?Current FCF multiple of Tatva Chintan Pharma Chem is (74.1x).
How many companies Tatva Chintan Pharma Chem has acquired to date?Tatva Chintan Pharma Chem hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Tatva Chintan Pharma Chem has invested to date?Tatva Chintan Pharma Chem hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Tatva Chintan Pharma Chem

Lists including Tatva Chintan Pharma Chem

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial